Nontraditional radiotherapy regimens for non-small-cell lung cancer

Ragulin Iu.A.; Gogolin D.V.

doi:https://doi.org/10.17116/onkolog20165258-63

Close metadata

Recommended articles:

The choice of radiotherapy dose fractionation regimen for grade 4 gliomas depending on the status of MGMT. P.A. Herzen Journal of Oncology. 2025;(1):13-18

Radiation therapy with focal dose escalation in the treatment of glioblastoma. P.A. Herzen Journal of Oncology. 2025;(2):64-69

Exosomal non-coding rnas as potential biomarkers in the diagnosis and prognosis of lung cancer. Review. Laboratory Service. 2024;(3):42-49

Problems of pregnancy planning and gestation in patients with diffuse toxic goiter after radiotherapy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):82-87

The first thousand of VATS anatomical lung resections at the Herzen Moscow Oncology Research Institute. Pirogov Russian Journal of Surgery. 2025;(6):7-18

Prognostic model and calculator for assessing the risk of prolonged pleural effusion after lobectomy. Pirogov Russian Journal of Surgery. 2025;(6):26-34

Fibrosing interstitial lung disease as a risk factor for lung cancer: a review of the literature and clinical case report. Journal of Respiratory Medicine. 2025;(2):51-59

Lean management example at the radiotherapy department. Medical Technologies. Assessment and Choice. 2025;(2):67-73

Survival of patients with malignant lung neoplasms in the Tomsk region (2013—2022). Russian Journal of Preventive Medicine. 2025;(7):43-49

Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review. Russian Journal of Archive of Pathology. 2025;(4):40-46

Abstract:

Radiotherapy (RT) plays an important role in the treatment of non-small-cell lung cancer (NSCLC) due to the fact that a considerable number of patients have contraindications to surgical treatment. However, the results of medical treatment for NSCLC cannot be considered satisfactory. Current techniques for treating RT can targetedly affect a tumor and minimize its negative impact on adjacent healthy tissues. This in turn opens the way for dose escalation and radiotherapeutic exposure optimization in each patient. This assumes particular importance in patients having contraindications to chemotherapy that needs the exposure to independent radical RT to be increased. The trials of the efficiency of different fractionation regimens have shown that the use of accelerated regimens is the most promising area in the treatment of NSCLC.

Keywords:

lung cancer

radiotherapy

nontraditional fractionation

Authors:

Ragulin Iu.A.

Meditsinskiĭ radiologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Obninsk

Gogolin D.V.

A.F. Tsyb Medical Radiology Research Centre, Branch, National Medical Radiology Center, Ministry of Health of the Russian Federation, Obninsk, Russia

Close metadata

References:

Haslett K, Pöttgen С, Stuschke M, Faivre-Finn С. Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer. J Thorac Dis. 2014;6(4):328-335. doi:10.3978/j.issn.2072-1439.2013.11.06.
Patterson C, Hocking M, Bond M, Teale C. Retrospective study of radiotherapy for lung cancer in patients aged 75 years and over. Age Ageing. 1998;27(4):515-518. doi:10.1093/ageing/27.4.515.
Kaprin A, Starinskii V, Petrova G, eds. Condition of the oncological help to the population of Russia in 2014 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2013]. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii; 2015. (In Russ.)
Mardynskii Yu, Gulidov I, Ivanova I, Kursova L, Zolotkov A, Kudryavtsev D, Ragulin Yu, Gogolin D. Results of application of the mode of the accelerated hyper fractionation in treatment of a nemelkokletochny cancer of lung. Sibirskii onkologicheskii zhurnal. 2010;2:11-14. (In Russ.)
Cox J, Pajak T, Asbell S, Russell A, Pederson J, Byhardt R et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993;27(3):493-498. doi:10.1016/0360-3016(93)90371-2.
Boiko A, Chernichenko A, Dar'yalova S, Meshcheryakova I, Ter-Arutyunyants S. Nonconventional fractionation of a dose. In: Materials V of the Russian oncological conference [Materialy V Rossiiskoi onkologicheskoi konferentsii]. Moscow, 27—29 November 2001. Moscow; 2001:120-122. (In Russ.)
Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688-697. doi:10.1148/90.4.688.
Perez CA, Stanley K, Grundy G, Hanson W, Rubin P, Kramer S et al. Impact of irradiation technique and tumour extent in tumour control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer. 1982;50(6):1091-1099. doi:10.1002/1097-0142(19820915)50:6<1091::aid-cncr2820500612>3.0.co;2-0.
Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of stage I—II non-small cell lung cancer. Chest. 2005;128(3):1461-1467. doi:10.1378/chest.128.3.146.
Katz H, Alberts RW. A comparison of high dose continuous and split course irradiation in non-oat cell carcinoma of the lung. Am J Clin Oncol. 1983;6:445-457. doi:10.1097/00000421-198308000-00010.
Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY et al. Effect of chemotherapy on locally advanced non-small lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys. 1991;20(6):1183-1190. doi:10.1016/0360-3016(91)90226-T.
Bradley DJ, Paulus R, Komaki R, Masters GA, Forster K, Schild SE et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(Suppl.):abstr.7501.
Cox J. Large-dose fractionation. (Hypofractionation). Cancer. 1985;55(9,Suppl.):2105-2111. doi:10.1002/1097-0142(19850501)55:9+<2105::aid-cncr2820551412>3.0.co;2-t.
Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation lung during radiotherapy. Acta Oncol. 1988;27:131-146.
Price A. Results of a survey of UK clinical oncologists. Presented at the Medical Research Council; 2001.
Din O, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF et al. Accelerated hypofractionated radiotherapy for non small cell lung cancer: Pooled results from 4 UK centres. Lung Cancer. 2010;67:S31-S32. doi:10.1016/s0169-5002(10)70097-0.
Lester J, Macbeth F, Brewster A, Court J, Iqbal N. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer. 2004;45(2):237-242. doi:10.1016/j.lungcan.2004.01.018.
Gressen E, Curran W. Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep. 2000;2(1):71-75. doi:10.1007/s11912-000-0013-0.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8(9):1543-1555.
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87(3):198-205. doi:10.1093/jnci/87.3.198.
Jeremic B, Milicic B. From conventionally fractionated radiation therapy to hyper-fractionated radiation therapy alone and with concurrent chemotherapy in patients with early stage non small cell lung cancer. Cancer. 2008;112:876-884. doi:10.1002/cncr.23240.
Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539-547.
Gouders D, Maingon P, Paesmans M, Rodrigus P, B Hahn B et al. Exclusive radiotherapy for inoperable stage I Non Small Cell Lung Cancer (NSCLC): a multicentric study. Lung Cancer. 2000;29(Suppl.1):166. doi:10.1016/s0169-5002(00)80560-7.
Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G et al. A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52(2):129-136. doi:10.1016/s0167-8140(99)00093-6.
Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M. Continuous, hyper-fractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiother Oncol. 1999;52:137-148.
Din OS, Lester J, Cameron A, Ironside J, Gee A, Falk S et al. The routine use of continuous, hyperfractionated, accelerated radiotherapy (CHART) for non-small cell lung cancer: a five centre experience. Int J Radiat Oncol Biol Phys. 2008;72(3):716-722. doi:10.1016/j.ijrobp.2008.01.033.
Saunders M, Rojas A, Lyn B, Wilson E, Phillips H. Dose-escalation with CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol. 2002;14(5):352-360. doi:10.1053/clon.2002.0121.
Belani C. Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol. 2005;23(16):3760-3767. doi:10.1200/jco.2005.09.108.
Nemkova E. Luchevaya terapiya v rezhime dinamicheskogo fraktsionirovaniya pri kombinirovannom lechenii neoperabel'nogo nemelkokletochnogo raka legkogo. Sankt-Petersburg; 2009. (In Russ.)
Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C et al. High dose radiation improved local tumour control and overall survival in patients with inoperable/unresectable non small cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324-333. doi:10.1016/j.ijrobp.2005.02.010.
Bradley J, Graham MV, Winter K et al. Toxicity and outcome results of RTOG 9311: a phase I—II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318-328. doi:10.1016/j.ijrobp.2004.06.260.
Rosenzweig KE, Fox JL, Yorke E et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non small cell lung carcinoma. Cancer. 2005;103:2118-2127. doi:10.1002/cncr.21007.
McGibney C, Holmberg O, McClean B et al. Dose escalation of CHART in NSCLC: is three dimensional conformal radiation therapy really necessary? Int J Radiat Oncol Biol Phys. 1999;45:339-350. doi:10.1016/s0360-3016(99)00095-4.
Sibley GS, Maguire PD, Anscher MA, Light K, Antoine P, Marks LB. High-dose accelerated radiotherapy for non-small cell lung cancer: 7360 cGy and beyond. Int J Radiat Oncol Biol Phys. 1999;45:241.
De Ruysscher D, Wanders R, van Haren E, Hochstenbag M, Geraedts W, Pitz C et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):132-138. doi:10.1016/j.ijrobp.2007.09.048.
Van Baardwijk A, Bosmans G, Boersma L et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;71:1394-1401. doi:10.1016/j.ijrobp.2007.11.070.
Thirion P, Holmberg O, Collins CD et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol. 2004;71:163-166. doi:10.1016/j.radonc.2003.09.006.
Belderbos JSA, De Jaeger K, Heemsbergen WD et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126-134. doi:10.1016/j.ijrobp.2006.04.034.
Lagerwaard FJ, Haasbeek CJ, Smit EF et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71:1118-1123. doi:10.1016/j.ijrobp.2007.10.053.
Hatton M, Hill R, Morgan S, Wilson P, Atherton P, Dickson J et al. Continuous Hyperfractionated Accelerated RadioTherapy — Escalated Dose (CHART-ED):A Phase I study. 2014 NCRI Cancer Conference. 2—5 November 2014: B274. Available at: http://conference.ncri.org.uk/abstracts/2014/abstracts/B274.html
Zolotkov A, Mardynsky Y, Ragulin Y, Medvedev V. Hyperfractionated accelerated radiotherapy with doze escalation in non-small cell lung cancer. J Thorac Oncol. 2009;4(9,Suppl.1):S954-S955. (Abstracts of the 13th World Conference on Lung Cancer. July 31-August 4, 2009. San Francisco, California, USA.)
Mauguen A, Le Péchoux C, Saunders M, Schild S, Turrisi A, Baumann M et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012;30(22):2788-2797. doi:10.1200/JCO.2012.41.6677.
Hatton MQ, Martin JE. Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions Clin Oncol (R Coll Radiol). 2010;22(5):356-364. doi:10.1016/j.clon.2010.03.010.